近日,减肥药巨头诺和诺德股价大跌约18%,市值蒸发625亿美元,约合4600亿元人民币。其市值急剧下跌的主要原因是该公司公布的减肥药物CagriSema临床数据未能达到市场预期,引发了投资者的广泛担忧。图片来源:摄图网市值蒸发625亿美元CagriSema是诺和诺德开发的一种用于治疗肥胖症或超重成人的药物,它是一种固定剂量的复方制剂,包含长效胰淀素类似物cagrilintide 2.4 mg和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.